Sugi Predict

Sugi Predict / Compounds / SCHEMBL875474

SCHEMBL875474

SCHEMBL875474

O=C(Nc1ccccc1)c1ccccc1OCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SGMS2 Q8NHU3 4/20 1.00
▸ GAA P10253 1/20 0.86
▸ MEN1 O00255 5/20 0.76
▸ KMT2A Q03164 5/20 0.76
▸ ALDH1A1 P00352 3/20 0.69
▸ NPC1 O15118 2/20 0.65
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ MAPT P10636 2/20 0.61
▸ L3MBTL1 Q9Y468 2/20 0.60
▸ LMNA P02545 1/20 0.60
▸ CASP3 P42574 1/20 0.60
▸ RAB9A P51151 1/20 0.60
▸ SENP7 Q9BQF6 1/20 0.60
▸ TDP1 Q9NUW8 1/20 0.60
▸ AKR1C3 P42330 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8203327 0.90 SGMS2 (0.82) SGMS2GAAMEN1KMT2AALDH1A1
SCHEMBL3814319 0.89 SGMS2 (0.80) SGMS2GAAMEN1KMT2AALDH1A1
SCHEMBL1650152 0.87 LRRK2 (0.77) SGMS2GAAMEN1KMT2AALDH1A1
SCHEMBL19133749 0.87 SGMS2 (1.00) SGMS2ALDH1A1
SCHEMBL30322841 0.87 SGMS2 (1.00) SGMS2ALDH1A1
SCHEMBL8205171 0.87 SGMS2 (0.76) SGMS2GAAMEN1KMT2AALDH1A1
SCHEMBL17551820 0.86 SGMS2 (0.77) SGMS2GAAMEN1KMT2ANPC1
SCHEMBL6748166 0.84 SGMS2 (0.72) SGMS2GAAMEN1KMT2AALDH1A1
SCHEMBL974381 0.84 SGMS2 (0.72) SGMS2GAAMEN1KMT2AALDH1A1
SCHEMBL1648383 0.84 MEN1 (1.00) SGMS2GAAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624161-B2 Estrogen receptor ligands and methods of use thereof GTX, INC. (US) 2017-04-18 — — US disclosed
US-9427418-B2 Estrogen receptor ligands and methods of use thereof GTX, INC. (US) 2016-08-30 — — US disclosed
US-9409856-B2 Estrogen receptor ligands and methods of use thereof GTX, INC. (US) 2016-08-09 — — US disclosed
US-20160031797-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF GTX, INC. 2016-02-04 — — US disclosed
US-9051267-B2 Estrogen receptor ligands and methods of use thereof GTX, INC. (US) 2015-06-09 — — US disclosed
US-20150087712-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF GTX, INC. 2015-03-26 — — US disclosed
US-20140187641-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF Gtx (US) 2014-07-03 — — US disclosed
EP-2747562-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF Gtx, Inc. (US) 2014-07-02 — — EP disclosed
US-20140171468-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF GTX, INC. (US) 2014-06-19 — — US disclosed
WO-2013043304-A9 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF GTX, INC. (US) 2014-04-24 — — WO disclosed
WO-2011106317-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF GTX, INC. (US) 2011-09-01 — — WO disclosed
US-20100267773-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF GTX, INC. 2010-10-21 — — US disclosed
WO-2010096801-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF GTX, INC. (US) 2010-08-26 — — WO disclosed
US-20090062341-A1 Nuclear receptor binding agents GTX, INC 2009-03-05 — — US disclosed
WO-2008130571-A1 NUCLEAR RECEPTOR BINDING AGENTS GTX, INC. (US) 2008-10-30 — — WO disclosed
EP-1954670-A2 NUCLEAR RECEPTOR BINDING AGENTS GTX Inc. (US) 2008-08-13 — — EP disclosed
US-20070265296-A1 Nuclear receptor binding agents GTX, INC. 2007-11-15 — — US disclosed
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-08-23 — — US disclosed
WO-2007062230-A2 NUCLEAR RECEPTOR BINDING AGENTS GTX, INC. (US) 2007-05-31 — — WO disclosed
US-7223759-B2 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187641-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF SHBG, AR, NR5A1 SGMS2 1599/4885GAA 2369/4885MEN1 2612/4885
US-20160031797-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF ESRRB, ESRRA, ESR2 SGMS2 2449/4885GAA 4258/4885MEN1 3937/4885
US-20070265296-A1 Nuclear receptor binding agents GPER1, ESRRG, ESR2 SGMS2 3911/4885GAA 4352/4885MEN1 1408/4885
US-20090062341-A1 Nuclear receptor binding agents GPER1, ESRRG, ESR2 SGMS2 3911/4885GAA 4352/4885MEN1 1408/4885
US-20100267773-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF SHBG, GNRHR, FSHR SGMS2 2655/4885GAA 4332/4885MEN1 3538/4885
US-20140171468-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF SHBG, GNRHR, FSHR SGMS2 2655/4885GAA 4332/4885MEN1 3538/4885
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds DDC, DPP3, AMPD3 SGMS2 4334/4885GAA 395/4885MEN1 3779/4885
US-20150087712-A1 ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF SHBG, AR, NR5A1 SGMS2 1599/4885GAA 2369/4885MEN1 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.